Preclinical study data published online in the scientific journal Nutrition & Diabetes reports that tetrahydrocannabivarin (THCV) — a naturally occurring analogue of THC — possesses positive metabolic effects in animal models of obesity. Researchers concluded: “Based on these data, it can be suggested that THCV may be useful for the treatment of the metabolic syndrome and/or type 2 diabetes (adult onset diabetes), either alone or in combination with existing treatments.”
Subjects who regularly consume cannabis possess favorable indices related to diabetic control as compared to occasional consumers or non-users, according to trial data published today online in the American Journal of Medicine. Commenting on the study, Editor-in-Chief Joseph S. Alpert, MD, Professor of Medicine at the University of Arizona College of Medicine, Tucson, said: “These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions.”